In the 2025 updated guidelines for type 2 diabetes mellitus (T2DM) management released by the International Diabetes Federation (IDF), the classic glucose-lowering drug metformin remains explicitly designated as the first-line foundational therapeutic agent. This recommendation is grounded in robust evidence accumulated over more than a century since its introduction, efficacy and safety repeatedly validated in […]